AAN 2011: Gilenya raises the bar for prospective MS market entrants.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      HONOLULU (Hawaii); HAWAII
    • Subject Terms:
      GENZYME Corp.; SANOFI-Aventis SA; EISAI Co. Ltd.
    • Abstract:
      The article focuses on the major developments on multiple sclerosis (MS) drugs highlighted at the 63rd American Academy of Neurology Annual Meeting (AAN) on April 9-16, 2011 in Honolulu, Hawaii. It notes that Eisai Co. Ltd. has presented the efficacy and long-term safety of the drug, Gilenya, based on the Phase II trial results. Moreover, Merck Serono SA has cited the effectiveness of its oral therapy, Movectro, while Sanofi-Aventis SA broadened its MS portfolio by acquiring Genzyme Corp.